AIMS: Herein we report on the successful isolation and establishment of a novel, long-term, primary, neurosphere-like cell line called 1603-MED from a 5-year-old boy affected by a highly aggressive anaplastic medulloblastoma. METHODS: Elaboration of the new protocol for neurosphere assay is extensively discussed, together with a complete immuno-histochemical and cytogenetic characterization of 1603-MED. RESULTS: Clinical course and histopathology are briefly discussed. The 1603-MED possesses a high capacity for proliferation, CD133 expression, self-renewal and differentiation, thus indicating that anaplastic medulloblastoma contains a subpopulation of cancer stem cells as observed in classic medulloblastoma. CONCLUSIONS: 1603-MED provides us with the first in vitro model of anaplastic medulloblastoma that may be suitable for studying both tumour progression and the genetic mechanisms related to therapy resistance, and may lead to the development and testing of chemosensitivity and new therapeutic targets.
AIMS: Herein we report on the successful isolation and establishment of a novel, long-term, primary, neurosphere-like cell line called 1603-MED from a 5-year-old boy affected by a highly aggressive anaplastic medulloblastoma. METHODS: Elaboration of the new protocol for neurosphere assay is extensively discussed, together with a complete immuno-histochemical and cytogenetic characterization of 1603-MED. RESULTS: Clinical course and histopathology are briefly discussed. The 1603-MED possesses a high capacity for proliferation, CD133 expression, self-renewal and differentiation, thus indicating that anaplastic medulloblastoma contains a subpopulation of cancer stem cells as observed in classic medulloblastoma. CONCLUSIONS: 1603-MED provides us with the first in vitro model of anaplastic medulloblastoma that may be suitable for studying both tumour progression and the genetic mechanisms related to therapy resistance, and may lead to the development and testing of chemosensitivity and new therapeutic targets.
Authors: Mark E P Prince; Li Zhou; Jeffrey S Moyer; Huimin Tao; Lin Lu; John Owen; Martin Etigen; Fang Zheng; Alfred E Chang; Jianchuan Xia; Gregory Wolf; Max S Wicha; Shiang Huang; Xiubao Ren; Qiao Li Journal: Oral Oncol Date: 2016-08 Impact factor: 5.337
Authors: Sylvia T Nürnberg; Augusto Rendon; Peter A Smethurst; Dirk S Paul; Katrin Voss; Jonathan N Thon; Heather Lloyd-Jones; Jennifer G Sambrook; Marloes R Tijssen; Joseph E Italiano; Panos Deloukas; Berthold Gottgens; Nicole Soranzo; Willem H Ouwehand Journal: Blood Date: 2012-09-12 Impact factor: 22.113